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applications in transdermal drug delivery
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A novel production process flow is presented here for the manufacture of hollow silicon microneedles
using deep reactive-ion etching (DRIE) technology. The patent-pending three-step process flow has been
developed to produce multiple arrays of sharp-tipped, hollow microneedles, which facilitate easy insertion
and controlled fluid injection into excised skin samples. A bevelled tip and vertical sidewalls for the
microneedle have been achieved with good uniformity, despite >45% open etch area. Processing steps
and etch challenges are discussed, and preliminary skin testing results are presented, showing effective
needle insertion and delivery of fluorescent dye into ex vivo skin from human breast tissue.
Introduction
Microneedles (MN) are becoming increasingly popular in
biomedical applications for several reasons: transdermal
insertion is regarded as painless and minimally invasive,
compared to traditional hypodermic needles;2,3 reduced
discomfort and fear of injection among patients;2–4 reduced risk
of infection.5,6 Microneedles do not have the same potential for
physical or infectious harm presented by conventional
hypodermic needles, and therefore use of hollow microneedles
in place of hypodermics would significantly decrease the risk of
sharps injuries to medical professionals.4,7–10
Microneedles are typically constructed from plastic,11,12
metal13 or silicon.14 Examples of hollow plastic needles are
available,11 however the majority of commercially available
polymer microneedles remain solid due to the difficulty
involved with integrating the bore.12,15,16 The plastic
moulding process also restricts flexibility in the design
whereas dry silicon etching allows for tailoring of processes
to individual applications, for example needle length to target
different skin depths.
Metal MNs are expensive to produce17 and it has proven
difficult to machine hollow metal MNs in a cost effective
production process. In terms of width dimensions, the 32G
hypodermic needle is similar to the hollow silicon microneedles
presented here, but the risk associated with the much increased
length of the hypodermic requires continuous training
programmes in order to be handled safely,18,19 and their use
results in more pain compared to microneedles.3
Hollow bevelled silicon microneedles have been
demonstrated,14 but in general their fabrication either relies
heavily on wet chemicals such as KOH or HF for the creation
of the bevelled surface,14,20–22 or plasma etching of the bevel
surface results in an unconventional needle shape.14,23
Advancements in dry etching technologies have made it
possible to develop a manufacture process flow that produces
repeatable silicon hollow bevelled microneedles.24
The novel process flow here benefits from the avoidance
of hazardous wet chemicals while maintaining a recognisable
and easily used needle shape. Additionally, the nature of the
semiconducting material further permits the future
development of an all-in-one diagnostic and therapeutic
(theranostic) device.25 Metal plating and dielectric deposition
on silicon means that a sensing microchip device with the
additional capability of administering medicines in relation
to data input from the MN sensor could be developed.25
Hollow microneedles hold a key advantage over the
multitude of available ‘solid’ microneedles; the ability to
inject a controlled dose. Solid microneedles do not give the
same benefit of pressured sub-dermal injection of fluids, and
instead rely on the passive diffusion of fluid through
previously created holes.12 This method is adequate for the
cosmetics industry,26 but does not deliver the precision
needed for state of the art medical applications. Additionally,
the bevelled tip of the microneedle decreases the insertion
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force required to break through a patient's stratum corneum,
reducing discomfort and potential issues with in situ breakage
due to application force.2,23,27
The primary focus of this article is to present a novel
process flow for the fabrication of hollow silicon
microneedles, exclusively using dry plasma processing
techniques. In addition to this, the results of a number of
proof of concept experiments are presented to show effective
insertion and injection of the MNs. However, at this stage
these biological tests are not intended to be comprehensive
and will be expanded upon in future studies.
Method
Etching and photolithography
Silicon wafers were purchased from Si-mat (Silicon Materials,
Germany) while photolithography resists and developer were
purchased from Microchemicals GmbH. Etching steps were
performed on a SPTS Technologies DSi-v RF plasma
processing chamber (Fig. 1).
A Laurell WS-650 spin coater was used to coat the wafers
with AZ125 NXT photoresist for the bevel and bore patterning
process, while a SUSS MicroTec AS8 spray coater was used to
deposit AZnLof2070 photoresist for the microneedle shaft
patterning. Photolithography resist patterning was hardened
using a SUSS MicroTec MA8 UV mask aligner that allows
backside alignment. Once patterned, wafer masking was
completed using AZ276 developer.
Characterisation
Proof of concept microneedle penetration characterisation was
performed using either full thickness porcine skin (Wetlab
Ltd. Warwicks, UK) or post-surgical human breast tissue
(under full ethical approval and informed patient consent,
local research ethics committee reference 08/WSE03/55).
Methylene blue, FITC-insulin and DIL (1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate), used for
characterisation of skin penetration efficacy, were purchased
(Sigma-Aldrich, Dorset, UK). An axial compression analyser
(Hounsfield/Tinius Olsen H1-KS, PA, USA) was used for
mechanical testing. Imaging was performed using fluorescent
microscopy (Zeiss Axio Imager M1, Germany) and ImageJ
software (Version 1.51k, National Institutes of Health, MD,
USA).
Plasma etch processing
A high density, inductively coupled plasma etch system was
used to etch the silicon for microneedle production. Due to the
requirements of the etched features the selected module was a
DSi-v from SPTS Technologies Ltd (Fig. 1). In this tool, the gas
enters the chamber thorough a central gas feed before being
excited to form a plasma using an RF coil around the top
chamber section. The plasma diffuses into the lower chamber,
which has a smaller volume compared to other DRIE (deep
reactive ion etching) machines, reducing the plasma residence
time. Lower residence time leads to a more effective etch step,
keeping larger features clean and free from process-induced
defects – which is critical for the production of silicon
microneedles. The wafer sits on a ceramic platen in the
chamber and is electrostatically clamped, allowing it to be
cooled by flowing helium to the backside of the substrate. RF
bias is applied to the platen to accelerate ions towards the wafer
surface, facilitating the physical element of DRIE.
The MN features were etched on die sizes typically 1.7 mm ×
7.5 mm, located on a 100 mm diameter wafer. The 100 mm
device wafers were carried on a 150 mm substrate, allowing
future development of a scalable process for larger (150 mm
diameter) wafers. Etched features were analysed using a
scanning electron microscope (SEM), to characterise and
quantify critical dimensions, surface roughness, and etch quality.
Fabrication steps
The novel process flow for dry etch silicon microneedle
fabrication (Fig. 2) consists of three main parts: the bevel
Fig. 1 Cross-section of SPTS Technologies Ltd DSi-v plasma etch
chamber. The central gas inlet leads to a low volume chamber for
plasma etching of silicon substrates.
Fig. 2 Process flow for hollow silicon microneedle production, patent
pending.1 Silicon wafers are shown in grey, with photoresist masks and
oxide stop layers shown in red and blue respectively.
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creation for the angled sharp MN tip [(A) or steps (a) to (c)];
the central bore etch, used for fluid transport within the MN
[(B) or steps (d) to (f)]; and the shaft etch, to determine the
length and consequently skin penetration depth [(C) or steps
(g) to (i)]. Photolithography steps were developed at the
Centre for Nanohealth, Swansea University, using AZ125 NXT
photoresist resist for steps (a) and (d) and spray coated
AZnLof2070 photoresist for step (g). Although this process
flow is designed for the manufacture of hollow microneedles,
solid microneedles can also be produced by simply removing
step (B) from the fabrication sequence.
Dry etch processes
Single step etch
Step (b) in the process flow (Fig. 2) is the creation of the
sloped surface required for the bevel of the microneedle. To
achieve this, a single step etch was setup whereby vertical
and lateral etching takes place in addition to simultaneous
passivation. In this case, platen RF bias applied during the
process provided ion bombardment to the base surface of the
feature.24 This physical assistance gave the etch some
directionality under conditions that would otherwise lead to
an isotropic etch form. This partial directionality during the
isotropic etch enabled tuning of the bevel angle and resulted
in the desired shape for microneedle bevel production.
Switched processing
Traditional switched etching consists of two steps, a polymer
deposition (typically consisting of C4F8) and an etch step.
Anisotropic 2-step DRIE protects the sidewall with the
deposition step, and then selectively etches the base of the
feature before returning to the deposition step, a sequence
known as the Bosch process.28 More recent switched etching
techniques are similar but commonly manifest as a three
step process (shown in Fig. 3), consisting of a polymer
deposition step (Dep; panel 2), a deposition removal step
(etch 1, E1; panel 3), and a silicon etch step (etch 2, E2; panel
4). While the separation of the etch step into E1 and E2 adds
to the complexity of the process, it also allows both steps to
be more effective. The base deposition is removed more
quickly by a physical E1, and the silicon is etched faster in
the chemical E2 to increase the overall process etch rate. The
separation of steps also has benefits in base roughness, as
the base deposition is cleared (with SF6, O2 or an SF6/O2
combination) before the dedicated etching of Si with SF6
begins. The cyclical repetition of steps (panels 5–7) produces
a directional anisotropic etch with close to vertical sidewalls
(panel 8), ideal for steps (e) and (h) of the microneedle
process flow (Fig. 2).
Process challenges
High open area. The successful etching of high open area
wafers (>30%) has long been a challenge for DRIE, as the
competition for fluorine radicals increases with the amount
of open silicon. This leads to ‘loading’ effects, where certain
parts of a wafer etch more quickly due to relatively lower
localised surrounding silicon, which has a detrimental effect
on etch depth uniformity. Large differences between these
areas (usually centre and edge) is highly undesirable as it can
render certain die unusable, reducing total yield.
Bore aspect ratio and depth. The bore etch is similar in
application to a traditional through-silicon via (TSV),29
however the etch depth of the microneedle bore is much
greater (up to 1.2 mm). A typical TSV etch would be
performed with the intention of connecting devices through
a thinned wafer, usually 200–500 μm thick with TSV critical
dimension (CD) 20–50 μm.29 In the microneedles case, the
TSV (bore) CD needs to be larger to accommodate fluid and
particulate flow down the length of the shaft. The TSV depth
is also greatly increased as the bore must reach from the top
bevelled surface of the wafer to the backside. As microneedle
production demands thick wafers to provide sufficient needle
insertion depth into skin, this requires dimensions of the
bore TSV to be approximately 100 × 1150 μm, more than
double the depth of other TSV applications.29 This significant
depth increase exaggerates the risk of process side effects
linked to high aspect ratio (AR) etches. Undesirable process
effects include wall roughness, grass, striations, and profile
changes.24 Process optimisations focussed on minimising




For the three etch stages shown in Fig. 2, the etch depth
uniformity was a particular challenge for the bevel (b) and
shaft (h) steps, as these were performed on patterns with
>45% total open area. To control the uniformity of these
applications, mask sets were designed whereby excess silicon
was available around the edge of the wafer. In the case of the
bevel etch (b), this change, in addition to process recipeFig. 3 3-Phase switched etching, illustrated step-by-step.
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optimisations of 25% RF power increase and 10 mT pressure
decrease, resulted in the etch depth uniformity improving
from >±11% to <±4% (Fig. 4). This exceeds the uniformity
expectation for a wafer with a pattern of this open area and
increases the number of usable die per wafer. A similar
improvement was also applied to the shaft etch (h), which
was optimised for depth uniformity <±3%.
Bevel etch
A peaked profile was achieved by undercutting the PR mask
with a single step dry etch process using SF6, C4F8, and O2
with a flow ratio approximately 6 : 1 : 1 at 70 mTorr chamber
pressure. 2500 W RF power was applied with the source coil,
and 40 W was used for the RF bias to the platen. Process
results are shown in Table 1.
Profile control is essential to produce the angled tip of the
needle. Pressure and platen bias were used to control the
level of anisotropy for this etch,24 and a favourable angle of
∼20° (Fig. 5) was thus created for the sharp MN tip, which
reduces the insertion force required.27 As well as limiting the
mechanical strain on the microneedle upon insertion, the
lower force needed to penetrate skin due to the ∼20° tip
results in less pain for patients.2,27 In other examples of
silicon microneedles, the needle tip is fabricated using a
chemical wet etch after the creation of the bore,14,22 which
can compromise bore quality and ultimately limits the final
microneedle shapes that can be produced. Processing the
needle tip by dry etching allows the bore and shaft to be
defined afterwards, thus avoiding wet chemicals and
associated process complications.
Bore etch
After being removed from the wafer carriers, bevelled wafers
were patterned for the bore step. This included a stop layer
on the bevel surface, shown in Fig. 2. Once patterning is
completed, wafers are rebonded to the carrier substrate with
the backside up to allow for the etching of the bore. While
bonded in this configuration, the bevels are protected from
damage by protrusions that prevent the sharp tips from
bearing weight. Fig. 6 shows a deep TSV etch demonstrated
on thick test wafers achieving 1157 μm depth with a via CD
of 100 μm using the 3-step switched process described above.
The Dep, E1, and E2 steps consisted of 450 sccm C4F8, 200/
100 sccm O2/SF6, and 720 sccm SF6, respectively. Across the
total process length, step times, chamber pressure, and
platen RF bias values were all varied to maintain a vertical
etch profile.
The AR of the bore is in line with current industrial
processes at >11 : 1,24,29 however, the depth presented here
Fig. 4 Graph comparing etch depths from edge to centre of wafer,
before and after improvements.
Table 1 Numerical results for all plasma etch steps in the microneedle
production flow
Parameter (units) Bevel Bore Shaft
Depth (μm) 500 1157 790
Etch rate (μm min−1) 8.5 8.1 6.2
Profile (°) ∼20.0 89.5 89.0
Selectivity (Si : PR) 90 16 74
Uniformity (±%) 4.0 1.1 2.2
Fig. 5 SEM image showing bevel-etched sharp tip for microneedles.
Fig. 6 SEM image showing bore, etched to a depth of 1157 μm on a
test wafer for fluid or cell transport.
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represents a significant increase on previously demonstrated
etches in terms of absolute depth with a circular TSV. 1157
μm is also deeper than ‘Ultra Deep Reactive Ion Etch’
(UDRIE) processes performed on trenches of a similar CD,
despite TSV's having limited species transport to the base of
the feature compared to trenches and therefore presenting
additional AR,24 etch rate, and depth challenges.30
Previously mentioned AR dependent effects24 were
eliminated by balancing Dep and E2 step times and pressures
to minimise damage to the feature, which produced a high
quality etch result, exceeding the depth required for MN
production. The straight profile does not restrict fluid
movement along the bore, while smooth sidewalls aid in
limiting turbulent flow and maintained cell viability in cell
delivery studies.31
Shaft etch
The shaft etch (Fig. 7) resulted in >89° pillar angle to a depth
of 790 μm. This was completed with medium source RF
powers and low chamber pressure in all three steps. The gas
flows were 360 sccm C4F8, 320 sccm SF6, and 315 sccm SF6
for Dep, E1, and E2 respectively. During the E1 and E2 steps,
platen RF bias was applied with 112 W and 36 W respectively;
this aids in maintaining a straight sidewall to the
microneedle. The achieved profile is key in maintaining
mechanical rigidity of the MN; too narrow at the base and
the wall thickness between the outside of the microneedle
and the central bore becomes a possible fracture point.27
This shape would also introduce the issue of an ‘arrowhead’
profile to the microneedle, which is more likely to become
lodged in a patient's skin.
Device integration
Fig. 8 shows the combination of the bore etch (Fig. 2e) with
the bevel etch (Fig. 2b). Additionally, the bevel (Fig. 2b) and
shaft (Fig. 2h) etches can be combined to produce solid
microneedles which can be used for insertion testing, as the
force required is the same for microneedles with or without
the central bore.27 The integration of the bore with the solid
needles offers no further process complications (Fig. 9).
The three processes in combination are used to fabricate a
hollow microneedle that can be produced in variable lengths,
depending on application. The MN die are then singulated
and mounted to syringe adaptors for delivery applications, or
coated with metals to create electrodes for theranostic use.25
Further improvements to the etch quality could be made
with optimisation of the masking and lithography steps.
Patterning PR on an angled surface such as the bevel
introduces unique challenges, where any PR defects present
Fig. 7 SEM image showing the shaft, etched for microneedle length
of 790 μm on a test wafer.
Fig. 8 SEM image showing the bore etch performed on a bevel
surface. The bore transfers to bevel wafers with no issues, stopping on
a backside layer.
Fig. 9 Silicon microneedle with central bore.1
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on the wafer surface results in roughness and isolated silicon
spikes during the etch. Within the current patterning regime,
the microneedle etch has been optimised to reduce these
effects by increasing the time of the shaft etch E2 step to
undercut any defects present on the bevel surface,




Axial compression tests (n = 3) were performed on 1 × 5 MN
arrays using a Hounsfield/Tinius Olsen compression analyser
(model H1-KS). A 50 N load cell enabled the compression
platform to descend, exerting an increasing force on the MNs
at a fixed rate of 4.5 mm s−1 to determine the point of
fracture. The analyser detected several MN fractures over a
compression distance of 250–400 μm, which is attributable to
each of the 5 MNs breaking over different compression
distances. The results indicate that the MN arrays withstand
a maximum force of 22 N before completely fracturing,
showing that a MN array has sufficient mechanical strength
to resist fracture upon thumb pressure insertion, which is
deemed to be <10N.32 Furthermore, as the compression
platform is composed of hard metal with little elasticity or
movement, it is likely that the MN will be able to withstand a
greater force upon penetration through the softer, elastic
skin.
Insertion testing
Proof of concept experiments were conducted using 1 × 5
microneedle arrays. A single array was glued to a syringe
adaptor that was attached to a syringe via a Luer-lock
(Fig. 11, Right). To determine whether the microneedles were
sharp enough to penetrate through the stratum corneum,
methylene blue staining was conducted, following insertion
of MNs. Methylene blue is a hydrophilic, low molecular
weight molecule that cannot diffuse through the hydrophobic
stratum corneum independently. Any exposure of the
hydrophilic viable cells beneath the stratum corneum would
stain blue, indicating that the stratum corneum had been
breached.33 Microneedles were inserted into porcine skin
(Wetlab Ltd. Warwicks, UK) via thumb pressure, stained with
methylene blue (Sigma-Aldrich, Dorset, UK) for five minutes
and washed with ethanol wipes. Fig. 10 shows visual
confirmation of the penetration of all five microneedles.
Skin penetration and fluid flow
To demonstrate microneedle penetration depths, optical
coherence tomography (OCT) on excised human breast tissue
(local research ethics committee reference 08/WSE03/55) was
performed (Fig. 11, Left). The OCT image clearly shows an
insertion profile, characteristic of a bevelled tip microneedle,
illustrating efficient microneedle penetration through the
stratum corneum. The total length of the microneedle pre-
penetration measured 700 μm, however, the OCT indicated
the microneedle formed an insertion channel profile of at
least 400 μm–57% of the original length. At this penetration
depth, it was confirmed that the bore of the microneedle was
fully inserted beneath the stratum corneum and into the
epidermis. Depth measurements were extracted using ImageJ
software.
Testing of hollow microneedles for their injection
potential was conducted using FITC-labelled insulin that
fluoresces under UV (ultraviolet) light. Fig. 11 (Right)
demonstrates a microneedle adaptor Luer-locked to a syringe.
Upon applying thumb pressure to the syringe plunger,
straight, consistent liquid jets were produced, indicating
FITC-insulin (Sigma-Aldrich, Dorset, UK) was able to flow
easily through the microneedle bores of three out of five
microneedles. The lack of flow in the two other microneedles
was due to adhesive blocking the bore.
Fig. 10 Visual skin penetration efficiency of 1 × 5 microneedle array,
stained with methylene blue. Imaged with a Samsung A70 (2019)
smartphone.
Fig. 11 Left; OCT imaging of excised human breast skin after the
application of a silicon microneedle. Right; FITC-insulin injection
through hollow microneedles attached to a syringe, imaged with a
Samsung A70 (2019) smartphone.
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Transdermal fluid injection
To confirm the capability of the microneedles for injection
into porcine skin, a syringe was loaded with DIL fluorescent
dye (Sigma-Aldrich, Dorset, UK) and attached to a syringe
pump; a constant flow rate of 10 μl min−1 was applied. 10 μl
of DIL was injected into porcine skin and the sample
immediately frozen in liquid nitrogen. Skin was then
sectioned vertically to a thickness of 8 μm using a cryostat
(Leica, Milton Keynes, UK) to visualise the microneedle
insertion profile and dye staining of the skin tissue
surrounding the injection site.
The micrograph (Fig. 12) shows a microneedle insertion
channel with a strongly fluorescent region at the apex of
where the MN was injected; this area fluoresces at the
emission wavelength 565 nm characteristic of DIL. As the dye
is highly concentrated at the base of the micro insertion
channel, this confirms the dye is injected via microneedle
penetration and not introduced through natural skin
conduits. The dye did not leak out over the microchannel
cavity and was retained at the base; this suggests that hollow
silicon microneedles are suitable for transdermal injection
and facilitate delivery of substances including pharmaceutical
compounds into epidermal and dermal skin layers.
Conclusions
The microneedles produced by the novel manufacture flow
(Fig. 2) presented here offer significant advantages over other
injection methods currently available. The sub-millimetre
construction limits the risk of injury4,7–10 and reduces pain in
patients via facile injection,2–4 potentially countering patient
phobia of hypodermic needle use.2,34 In addition to the benefits
over conventional hypodermic injection, the hollow bevelled
silicon microneedle allows for greater versatility than other
microneedles. Forced injection through the centre TSV (bore)
allows for controlled fluid volume delivery, whilst the sharp
bevelled tip limits pain for patients by reducing insertion
force.2,27 In addition, the semiconducting base material
introduces a pathway to future theranostic device chips.25
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